Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Graft Versus Host Disease: Atypical Presentations & Nail Disease

Description

The presentation by Dr. Rana, a dermatologist at Stanford and director of the nail clinic, focuses on graft versus host disease (GVHD) and its effects, particularly on nail health. She discusses the varied manifestations of chronic GVHD, including presentations that resemble conditions like lichen planus and psoriasis. Through illustrative clinical cases, Dr. Rana highlights the challenges in diagnosing and treating GVHD, emphasizing the crucial role of dermatologists in these scenarios. She notes that nail disease often goes unrecognized in traditional GVHD assessments, despite potentially affecting up to 50% of patients. The talk also covers common presentations of nail GVHD, the implications of autoimmune conditions in transplant patients, and treatment strategies, including intralesional steroid injections. Dr. Rana stresses the importance of monitoring for secondary infections and malignancies, given the immune suppression experienced by these patients. Ultimately, she advocates for the consideration of nail health in GVHD management due to its significant impact on patient quality of life.

View more

Conclusions

  • Chronic graft-versus-host disease (cGVHD) exhibits diverse and atypical presentations that can significantly affect diagnosis and treatment approaches.
  • Nail involvement occurs in 20-50% of patients with some form of graft-versus-host disease (GVHD), mainly resembling lichen planus.
  • Management of nail GVHD includes systemic treatments, but early and aggressive interventions can help prevent scarring.
  • Nail alterations are not just diagnostic markers; they can indicate underlying complications such as infections and secondary malignancies.
  • Morphological features of GVHD can guide targeted therapies that aim to minimize systemic immune suppression, improving patients' overall outcomes.
  • Cornejo CM, Kim EJ, Rosenbach M, Micheletti RG. Atypical manifestations of graft-versus-host disease. J Am Acad Dermatol. 2015 Apr;72(4):690-5. doi: 10.1016/j.jaad.2014.12.022. Epub 2015 Jan 29. PMID: 25641626.
  • Patel AR, Pavletic SZ, Turner ML, Cowen EW. The isomorphic response in morphealike chronic graft-vs-host disease. Arch Dermatol. 2008 Sep;144(9):1229-31. doi: 10.1001/archderm.144.9.1229. PMID: 18794477; PMCID: PMC2593893.
  • Park JH, Lester L, Kim J, Kwong BY. Acral verruca-like presentation of chronic graft-vs .- host disease. J Cutan Pathol. 2016 Mar;43(3):236-41. doi: 10.1111/cup.12640. Epub 2015 Nov 5. PMID: 26449730.
  • Mary Larijani, Diana Zarowin, Anne Wohlschlaeger, Marissa J Perman, James R Treat. Chronic graft-versus-host disease and inhibition of interleukin-17: proof of concept in humans. PMID: 36268606 DOI: 10.1111/pde.15146
  • Dai J, Hight RS, Grullon K, Xiao TL, Stein SL. Vitiligo-like manifestations of graft-versus-host disease in a pediatric population. Pediatr Dermatol. 2023 Jan;40(1):157-161. doi: 10.1111/pde.15121. Epub 2022 Sep 5. PMID: 36063124.
  • Bang CH, Park HE, Kim YH, Jung JH, Lee JH, Park YM, Han JH. Risk of Subsequent Vitiligo in Transplant Recipients With Comorbid Graft-vs-Host Disease. JAMA Dermatol. 2024 Feb 1;160(2):194-198. doi: 10.1001/jamadermatol.2023.4933. PMID: 38091023; PMCID: PMC10719831.
  • Zuo RC, Naik HB, Steinberg SM, Baird K, Mitchell SA, Kuzmina Z, Pavletic SZ, Cowen EW. Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. JAMA Dermatol. 2015 Jan;151(1):23-32. doi: 10.1001/jamadermatol.2014.1550. PMID: 25207994; PMCID: PMC7703696.
  • DePry JL, Vyas R, Lazarus HM, Caimi PF, Gerstenblith MR, Bordeaux JS. Cutaneous Malignant Neoplasms in Hematopoietic Cell Transplant Recipients: A Systematic Review. JAMA Dermatol. 2015 Jul;151(7):775-82. doi: 10.1001/jamadermatol.2015.121. PMID: 25902409.
  • Pendlebury GA, Bongiorno MA, Lackey JN. Aggressive Cutaneous Squamous Cell Carcinomas Following Treatment for Graft-versus-Host Disease: A Case Report and Review of Risk Factors. Dermatopathology (Basel). 2022 Mar 31;9(2):122-130. doi: 10.3390/dermatopathology9020015. PMID: 35466244; PMCID: PMC9036292.
  • Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1. doi: 10.1016/j.bbmt.2014.12.001. Epub 2014 Dec 18. PMID: 25529383; PMCID: PMC4329079.